To nominate a deserving company (whether your own or those in your network/portfolio/community), please follow this link and complete the requested information.

The deadline for nominations is Monday, December 16th.

Technology Startup

A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.

Criteria:

• Company should have been founded, launched meaningful operations, or pivoted to current strategic focus at some point in the period between January 1, 2021, and December 31, 2024.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

Key Considerations:

• Product or service innovation including market need or assessment.
• Potential for significant growth.
• The management team and its ability and record of achieving success.
• A demonstration of success such as significant milestones, raising capital, and revenue.

Technology Emerging

A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.

Criteria:

• Company must have been in operation before January 1, 2021.
• Revenues must be less than $50 million. *If revenues are projected to exceed $50m in 2024, please complete the Technology Company application.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

Key Considerations:

• Product or service innovation, including proprietary technology or other advantage.
• Company milestones including strategic decisions made by management that led to growth in revenues and/or earnings.
• Strength of management team including ability to raise capital.
• Demonstration of a sustainable and scalable business model.

Technology Company of the Year

A technology company must either provide proprietary technology or intellectual property or services that leverage proprietary technology or IP.

Criteria:

• Company with more than $50 million in revenues projected for the current fiscal year.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

Key Considerations:

• Leadership and product and/or service innovation in an industry or market.
• Significant company milestones including financial accomplishments.
• The Company’s connection and commitments to the Greater Philadelphia region through community and industry involvement.

Technology Investment Deal

Criteria:

• Company with more than $50 million in revenues projected for the current fiscal year.
• Deal must have been fully executed between November 1, 2023, and October 31, 2024.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees and consultants must be based in the region.
• Events that qualify for this category include: IPO; Capital Raise; Buy-Side Merger & Acquisition Transaction; Sell-Side Merger & Acquisition Transaction

Key Considerations:

• Realized returns for the investors and management.
• EBITDA margin and revenue growth.
• Strategic considerations of the deal (e.g. commercial strategy, innovation, and contribution to market development.
• Company performance prior to transaction.
• How the sale or purchase impacted the broader industry(s) of the buyer and/or seller.

Life Sciences & Healthcare Startup

Criteria:

• Company should have been founded, launched meaningful operations, or pivoted to current strategic focus at some point between January 1, 2021, and December 31, 2024.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

Key Considerations:

• Product innovation including unmet market need and how that is uniquely addressed by your product/service.
• The management team and its ability and record of achieving success.
• Provide demonstration of success (e.g., significant milestones, raising capital, revenue, etc.).
• Describe the R&D investment strategy.
• What did the company do to overcome challenges in financing, development, or commercialization?

Life Sciences & Healthcare Emerging

Criteria:

• Company must have been in operation beginning on January 1, 2021.  The Company should have no more than 8 years of operating results since its founding.
• Must have sales, grants, or licensing fees.

• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

Key Considerations:

• Describe product or service, including proprietary applications or other competitive advantage.
• The impact on the clinical problem this product or innovation is trying to solve (e.g. saving a hospital money on a procedure, making a clinician more productive, etc.).
• Company milestones including strategic decisions made by the management team that led to growth in revenues and/or earnings, corporate collaborations, or license deals (e.g. ability to raise capital, strategy to achieve breakeven, ability to realize high gross margins, etc.).

Life Sciences & Healthcare Company of the Year

Criteria:

• Company must have at least four years of operating results in industry segments such as specialty pharmaceuticals, biotechnology, medical devices, instrumentation, therapeutics, diagnostics, health tech, etc.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees, and consultants must be based in the region.

Key Considerations:

• Company should demonstrate the impact of a proprietary product to the patient and/or clinician or research and development of an innovative product and its potential impact on the market.
• Company should demonstrate its ability to raise capital; achieve success in its development strategy and clinical pathway; commercialize and generate revenue.
• Describe any significant events, e.g. product discovery, drug registration, commercial launch, an exit, an increase in sales, etc. that occurred in 2022.
• What did the company do to overcome challenges in financing, development, or commercialization?

Life Sciences & Healthcare Investment Deal

Criteria:

• Deal must have been fully executed between November 1, 2023, and October 31, 2024.
• Company must have its HQ or significant operations in the region and a significant portion of its leadership, employees and consultants must be based in the region.
• Events that qualify for this category include: IPO; Capital Raise; Buy-Side Merger & Acquisition Transaction; Sell-Side Merger & Acquisition Transaction

Key Considerations:

• Realized returns for the investors and management.
• EBITDA margin and revenue growth.
• Strategic considerations of the deal (e.g. commercial strategy, innovation, and contribution to market development.
• Company performance prior to transaction.
• How the sale or purchase impacted the broader industry(s) of the buyer and/or seller.